

CURRENT LISTING OF CLAIMS

1. (Original) A method of treating an HIV-infected individual, comprising:
  - (a) treating an HIV-infected individual with at least one anti-retroviral compound;
  - (b) immunizing said individual with an HIV immunogenic composition;
  - (c) withdrawing treatment with said anti-retroviral compound;
  - (d) reinitiating treatment with at least one anti-retroviral compound;
  - (e) repeating step (c) at least once; and
  - (f) optionally repeating step (d) at least once.
2. (Original) The method of claim 1, wherein said immunization induces an anti-HIV CD4+ T helper cell response.
3. (Original) The method of claim 1, wherein said immunization comprises administering said HIV immunogenic composition more than once.
4. (Original) The method of claim 1, wherein said HIV immunogenic composition comprises a whole-killed HIV virus devoid of outer envelope protein gp120.
5. (Original) The method of claim 1, wherein said HIV immunogenic composition comprises an adjuvant.
6. (Original) The method of claim 5, wherein said adjuvant comprises incomplete Freund's adjuvant
7. (Original) The method of claim 1, wherein said HIV immunogenic composition comprises at least one immunostimulatory sequence (ISS).
8. (Original) The method of claim 1, wherein said HIV immunogenic composition is REMUNE™.

9. (Original) The method of claim 1, wherein said HIV immunogenic composition is a combination of REMUNE<sup>TM</sup> and at least one ISS.

10. (Original) The method of claim 1, wherein said anti-retroviral compound is selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor and a ribonucleotide reductase inhibitor.

11. (Original) The method of claim 1, wherein said anti-retroviral compound is selected from the group consisting of a viral adsorption inhibitor, an HIV entry inhibitor, an integrase inhibitor and a virus-cell fusion inhibitor.

12. (Original) The method of claim 1, wherein said anti-retroviral treatment in step (a) reduces HIV viral load to less than 5000 copies/ml.

13. (Original) The method of claim 1, wherein said anti-retroviral treatment in step (a) reduces HIV viral load to less than 500 copies/ml.

14. (Original) The method of claim 1, wherein said anti-retroviral treatment in step (a) reduces HIV viral load to 25 less than 50 copies/ml.

15. (Original) The method of claim 1, wherein said withdrawal in step (c) is for a period of time until viral load rises to greater than about 100,000 copies/ml.

16. (Original) The method of claim 1, wherein said 5 withdrawal in step (c) is for a period of time until viral load rises to greater than about 50,000 copies/ml.

17. (Original) The method of claim 1, wherein said withdrawal in step (c) is for a period of time until viral load rises to greater than about 20,000 copies/ml.

18. (Original) The method of claim 1, wherein said withdrawal in step Cc) is for a period of at least 2 weeks.

19. (Original) The method of claim 1, wherein said withdrawal in step (c) is for a period of about 8 weeks.

20. (Original) The method of claim 1, wherein reinitiating 15 said anti-retroviral treatment in step (d) reduces HIV viral load to less than 5000 copies/ml.

21. (Original) The method of claim 1, wherein reinitiating said anti-retroviral treatment in step (d) reduces HIV viral load to less than 500 copies/ml.

22. (Original) The method of claim 1, wherein reinitiating said anti-retroviral treatment in step (d) reduces HIV viral load to less than 50 copies/ml.

23. (Original) The method of claim 1, wherein said reinitiated anti-retroviral treatment in step (d) is for a 25 period of about 8 weeks.

24. (Original) The method of claim 1, wherein HIV viral load in said individual following step (e) is maintained at less than about 10,000 copies/ml for a period of at least about 8 weeks.

25. (Original) The method of claim 1, wherein HIV viral load in said individual following step (e) is maintained at less than about 5,000 copies/ml for a period of at least about 8 weeks.

26. (Original) The method of claim 1, wherein HIV viral 10 load in said individual following step (e) is maintained at less than about 500 copies/ml for a period of at least about 8 weeks.